Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:03:32.314Z.
Calculation as of: 2026-10-06T16:03:32.314Z.
Quote observation: 2026-10-06T16:00:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 84870b41b004d4a356f3546a7a12828ec10b1f950fc42869db9e2e4c5d55c05b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$541.30M
EV/EBIT Ratio
N/A
TTM Avg
189.50x
3Y Avg
189.50x
5Y Avg
189.50x
Market Cap
$542.85M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | $534.86M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $541.30M | N/A | 189.50x | 189.50x | 189.50x |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $542.85M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $522.80M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $522.93M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $520.22M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $510.38M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $554.42M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $554.85M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
